Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Systemic sclerosis (SSc) is a potentially fatal autoimmune disorder with limited therapeutic options. Sclerodermatous
graft versus host disease
(sclGvHD), induced by transfer of B10.D2 splenocytes into BALB/c
Rag2
-/-
mice, models an inflammatory subset of SSc characterized by a prominent IL13-induced gene expression signature in the skin. Host mice deficient in
IL4RA
, a subunit of the type II IL4/IL13 receptor, are protected from sclGvHD. While
IL4RA
has a well-established role in Th2 differentiation and alternative macrophage activation, we report here a previously unappreciated function for
IL4RA
in lymphatic endothelial cells (LECs): regulation of activated T cell egress. Seven days after splenocyte transfer,
Il4ra
-/-
hosts had increased numbers of activated graft CD4
+
T cells in skin draining lymph nodes (dLNs) but fewer T cells in efferent lymph, blood, and skin. Sphingosine-1 phosphate (S1P), master regulator of lymphocyte egress from LNs, was lower in dLNs of
Il4ra
-/-
hosts with a corresponding decrease of S1P kinase 1 (
Sphk1
) expression in LECs. Bypassing the efferent lymphatics via i.v. injection of CD4
+
T cells from dLNs of
Il4ra
-/-
sclGvHD mice restored clinical GvHD in secondary
Il4ra
-/-
recipients. These results identify a role for
IL4RA
and suggest that modulation of lymphocyte egress from LNs may be effective in SSc and GvHD.
...
PMID:IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. 2754 23